Rameen Kasana
Tue, June 23, 2026 astatine 10:36 AM CDT 2 min read
According to JPMorgan, the remainder of the twelvemonth and beyond look arsenic an execution play for the company, with "relatively sparse near-term stock-moving catalysts." The steadfast finds it hard to spot a way to upside successful the adjacent term, particularly fixed the company's further currency needs to powerfulness signifier 3 development. The company's antagonistic returns are understandable, considering its 572% upside potential. With beardown imaginable for aboriginal gains, Upstream Bio, Inc. (NASDAQ:UPB) is among the champion low-priced stocks to get affluent successful 2026.
Copyright: dolgachov / 123RF Stock Photo
Back connected June 3, Matthew Caufield from H.C. Wainwright began sum of Upstream Bio, Inc. (NASDAQ:UPB) with a Buy standing and $36 terms target. The expert believes Verekitug is simply a caller antibody antagonist of the thymic stromal lymphopoietin receptor, with "sights connected efficacy and differentiated quarterly subcutaneous dosing."
Upstream Bio, Inc. (NASDAQ:UPB), incorporated successful 2021, is simply a Massachusetts-based clinical-stage biotechnology institution specializing successful solutions for terrible respiratory disorders.
While we admit the imaginable of UPB arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years
Disclosure: None. Follow Insider Monkey connected Google News.

6 hours ago
3





English (CA) ·
English (US) ·
Spanish (MX) ·